Fortis Healthcare Delivers Strong Q3 FY26 Performance Amidst Strategic Expansion

Fortis Healthcare Limited, a prominent integrated healthcare provider in India, has reported a robust financial performance for the third quarter of fiscal year 2026, ending December 31, 2025. The company demonstrated significant growth across its hospital and diagnostics segments, despite the seasonal impact of festivals in key geographies. Consolidated revenues for Q3 FY26 surged by 17.5% year-on-year to INR 2,265 crore, while operating EBITDA witnessed an impressive 34.8% increase to INR 505 crore, pushing the operating EBITDA margin to a healthy 22.3% from 19.4% in the corresponding previous period. Profit Before Tax (PBT) before exceptional items also grew by 21.9% to INR 312 crore, underscoring the company's operational efficiency.

Segmental Performance and Growth Drivers

The hospital business was a key driver of this strong performance, with revenues growing by 19.4% year-on-year to INR 1,938 crore. The operating EBITDA for the hospital segment increased by 28.9%, with margins improving to 21.7% from 20.0% in Q3 FY25. This growth was primarily fueled by a 14% increase in occupied beds, reaching 3,189 beds, and a 4.5% rise in Average Revenue Per Occupied Bed (ARPOB) to INR 2.56 crore per annum. The ARPOB improvement was attributed to a favorable case mix and an increase in high-end procedures, including a 52% year-on-year increase in robotic surgeries. Revenues from digital channels also saw an 18.9% year-on-year growth, contributing approximately 30% to overall hospital revenues.

In the diagnostics business, operated by Agilus Diagnostics, gross revenues grew by 8.3% year-on-year to INR 371 crore. The operating EBITDA for this segment showed a substantial improvement of 73.5%, with margins reaching 23.1% compared to 14.4% in Q3 FY25. Agilus conducted approximately 9.94 million tests during the quarter and expanded its network by adding over 175 new customer touchpoints. The revenue contribution from the preventive portfolio increased to 12% from 10% in Q3 FY25, while the specialized portfolio's contribution rose to 35% from 33%.

Here is a financial summary of Fortis Healthcare's Q3 FY26 performance:

Strategic Initiatives and Future Outlook

Fortis Healthcare continues to execute its cluster-based inorganic growth strategy. A significant development was the acquisition of the 125-bedded People Tree Hospital in Yeshwanthpur, Bengaluru, for INR 430 crore in January 2026. This acquisition, through TMI Healthcare Pvt. Ltd., includes an adjacent land parcel, enabling future expansion to over 300 beds. The company aims to transform this facility into a high-end, 300-bedded super specialty hospital within 3-4 years, despite its current sub-optimal performance requiring initial investment.

In November 2025, Fortis launched 'Adayu', a 36-bedded specialized mental health care facility in Gurugram, addressing the growing awareness of mental health. The company's bed expansion plans are progressing well, with approximately 750 operational beds added in FY26 across various facilities, including Manesar, Noida, and Faridabad. The flagship FMRI hospital is also undergoing a 200-plus bed expansion, with the first 100 beds expected to be operationalized soon.

On the medical excellence front, Fortis launched several advanced programs in Q3 FY26, including a dedicated Advanced Spine Centre in Bengaluru, an Ocular Oncology Clinic in Gurugram, and an AI-powered Advanced Therapeutic GI Endoscopy Department in Jaipur. The company also introduced advanced robotic surgical systems and established the Fortis Cancer Institute and Institute of Gastro Sciences in Mulund. These initiatives underscore Fortis's commitment to enhancing clinical capabilities and patient care.

Management Commentary and Investor Confidence

Management acknowledged the increase in net debt to INR 2,547 crore, primarily due to funding strategic acquisitions. However, they expressed confidence in having sufficient room for further growth aspirations and highlighted the potential for equity infusion from IHH, which could be used for debt reduction or future growth opportunities. The company expects to maintain its current growth trajectory for at least the next two years and anticipates a 4-5% ARPOB increase annually, driven by a favorable case mix.

While acknowledging challenges in certain units like Gleneagles (which experienced negative growth) and Jaipur (which requires strengthening its clinical program), management demonstrated transparency and a clear plan for course correction. The divestment of the Richmond Road, Bangalore facility in December 2024 also reflects a disciplined approach to asset management. Fortis Healthcare's Q3 FY26 results reflect a period of strong operational performance, strategic expansion, and a clear vision for sustained growth, reinforcing investor confidence in its long-term trajectory.